Generate BiomedicinesGENB +2.18%6 EBIT per Share is $ as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 1,181 Biotechnology companies, Generate Biomedicines ranks worse than 84673.92% on this metric.
Generate Biomedicines's EBIT per Share for the
six
months ended in Dec. 2025 was $-2.17.
Generate Biomedicines does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Generate Biomedicines's EBIT per Share or its related term are showing as below:
GENB's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.5 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Generate Biomedicines (NAS:GENB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Generate Biomedicines EBIT per Share Related Terms
Generate Biomedicines EBIT per Share Historical Data
* Premium members only.
The historical data trend for Generate Biomedicines's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Generate Biomedicines (GENB) has a EBIT per Share of $ as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #999999 out of 1181 companies in the Biotechnology industry.
Is Generate Biomedicines' EBIT per Share too high?
Generate Biomedicines' current EBIT per Share is $. Based on the distribution chart, Generate Biomedicines ranks #999999 out of 1181 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' EBIT per Share compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #999999 out of 1181 companies for EBIT per Share. This places Generate Biomedicines in the lower half of its industry. The industry median EBIT per Share is 15.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.50, based on 1,181 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Generate Biomedicines and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Generate Biomedicines's current EBIT per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current EBIT per Share of $. The current EBIT per Share is $. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current EBIT per Share is $ as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score
Get the complete analysis for GENB
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENB has been successfully added to your 